Breaking News Instant updates and real-time market news.

AGN

Allergan

$210.52

5.57 (2.72%)

, SHPG

Shire

$153.14

1.59 (1.05%)

12:56
10/02/17
10/02
12:56
10/02/17
12:56

Wells Fargo says Allergan discounting, rebating for Restasis typical of industry

Wells Fargo analyst David Maris noted that Shire (SHPG) filed an antitrust suit against Allergan (AGN) over its discounting and rebating for Restasis. However, what Shire claims is an anti-competitive scheme is no different from the normal course in the industry, said Maris. The analyst keeps an Outperform rating on Allergan shares.

AGN

Allergan

$210.52

5.57 (2.72%)

SHPG

Shire

$153.14

1.59 (1.05%)

  • 01

    Nov

AGN Allergan
$210.52

5.57 (2.72%)

09/25/17
WELS
09/25/17
NO CHANGE
WELS
Outperform
Allergan Refusal to File for Vraylar 'surprising,' says Wells Fargo
Wells Fargo analyst David Maris notes that Allergan received a Refusal to File letter from the FDA regarding its Supplemental New Drug Application, or sNDA, seeking approval for Vraylar, or cariprazine, for the treatment of negative symptoms associated with schizophrenia in adult patients. The analyst believes the news is the latest in a string of setbacks for the company, and says it is" surprising" given management highlighted this indication as a potential growth driver a few weeks ago and did not mention any potential issues with the filing timing. Maris reiterates an Outperform rating on the shares.
09/25/17
WELS
09/25/17
NO CHANGE
WELS
Outperform
Allergan buyback should be seen as good news, says Wells Fargo
Wells Fargo analyst David Maris believes the buyback announcement this morning from Allergan should be taken as good news. The departure of CFO Tess Hilado may create greater uncertainty, but company's reaffirmation of 2017 guidance and Q3 revenue projections are offsetting positives, Maris tells investors in a research note. He keeps an Outperform rating on Allergan.
09/26/17
UBSW
09/26/17
NO CHANGE
Target $275
UBSW
Buy
Allergan weakness a buying opportunity, says UBS
UBS analyst Marc Goodman said the recent weakness in Allergan is a buying opportunity. He believes he may have been too aggressive with his model, but even with his revised forecast, he said the story and valuation does not change that much and the stock remains very attractive. Goodman said the risk/reward for the Restasis patent case is not good, but he believes the shares have already priced in the risk. Goodman reiterated his Buy rating and $275 price target on Allergan shares.
09/26/17
FBCO
09/26/17
NO CHANGE
Target $266
FBCO
Outperform
Allergan price target lowered to $266 from $286 at Credit Suisse
Credit Suisse analyst Vamil Divan lowered his price target for Allergan to $266 from $286 following recent news flow on the name, most notably the Refusal to File letter that the company received from the FDA on the Vraylar label expansion and the new $2B share repurchase program. The analyst reiterates an Outperform rating on the shares.
SHPG Shire
$153.14

1.59 (1.05%)

07/11/17
COWN
07/11/17
NO CHANGE
Target $325
COWN
Outperform
Shire hemophilia franchise being valued near zero, says Cowen
Cowen analyst Ken Cacciatore believes Shire's (SHPG) current valuation reflects essentially no value for the company's hemophilia franchise. Investors are treating Shire/Baxalta's hemophilia franchise as if it should equate to essentially zero, into perpetuity, beginning in 2020, Cacciatore tells investors in a research note, citing his analysis. He believes this sentiment, based on competitive concerns from Roche (RHHBY) and Alnylam (ALNY), is a "gross overreaction." The analyst has an Outperform rating on Shire with a $325 price target.
07/14/17
CANT
07/14/17
NO CHANGE
CANT
Worries about Shire hemophilia franchise overdone, says Cantor
After speaking with a pediatric hematology/oncology physician, Cantor analyst Louise Chen reports that the doctor said that uptake of Roche's (RHHBY) hemophilia treatment, ACE910, "will be gradual" because of safety concerns. The analyst says that worries about Shire's (SHPG_) hemophilia franchise are overdone. She keeps a $222 price target and an Overweight rating on the stock.
08/16/17
EVER
08/16/17
INITIATION
Target $196
EVER
Outperform
Shire initiated with an Outperform at Evercore ISI
Evercore ISI analyst Josh Schimmer initiated Shire with an Outperform and a $196 price target.
08/22/17
JEFF
08/22/17
NO CHANGE
JEFF
Buy
Shire CFO departure timing 'inopportune,' says Jefferies
Jefferies analyst David Steinberg called the "surprising move" of Shire CFO Jeff Poulton out of his current post and into a role at an agriculture biotech start-up "naturally raises some concerns" given the recent departure of the company's head of R&D, adding that the timing is "highly inopportune." However, after speaking with Poulton, the analyst's take is that the move is motivated by an interest in a more entrepreneurial opportunity. Steinberg keeps a Buy rating on Shire shares, which slid 3% yesterday.

TODAY'S FREE FLY STORIES

CS

Credit Suisse

$15.22

0.405 (2.73%)

14:25
07/16/18
07/16
14:25
07/16/18
14:25
Options
Credit Suisse call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BECN

Beacon Roofing

$39.77

-0.19 (-0.48%)

14:21
07/16/18
07/16
14:21
07/16/18
14:21
Hot Stocks
Beacon Roofing acquires Atlas Supply »

Beacon Roofing Supply…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOC

Northrop Grumman

$320.52

-1.28 (-0.40%)

, BA

Boeing

$355.82

5.01 (1.43%)

14:17
07/16/18
07/16
14:17
07/16/18
14:17
Periodicals
Talent scarce for defense firms despite jump in military spending, NYT says »

According to the New York…

NOC

Northrop Grumman

$320.52

-1.28 (-0.40%)

BA

Boeing

$355.82

5.01 (1.43%)

LMT

Lockheed Martin

$318.09

-0.35 (-0.11%)

GD

General Dynamics

$191.29

-1.5 (-0.78%)

RTN

Raytheon

$199.63

-0.09 (-0.05%)

UTX

United Technologies

$129.14

-0.4 (-0.31%)

BAESY

BAE Systems

$0.00

(0.00%)

GOOG

Alphabet

$1,186.00

-2.81 (-0.24%)

BABA

Alibaba

$190.58

0.55 (0.29%)

FB

Facebook

$208.14

0.81 (0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 17

    Jul

  • 23

    Jul

  • 24

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 08

    Aug

  • 10

    Sep

  • 18

    Sep

  • 28

    Oct

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
07/16/18
07/16
14:17
07/16/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
07/16/18
07/16
14:16
07/16/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HUBG

Hub Group

$49.00

-1.95 (-3.83%)

14:10
07/16/18
07/16
14:10
07/16/18
14:10
Options
Unusually large option print in Hub Group as shares slump »

Unusually large option…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:10
07/16/18
07/16
14:10
07/16/18
14:10
General news
Fed's Kashkari worries about the flattening yield curve »

Fed's Kashkari…

JBHT

J.B. Hunt

$120.99

-0.78 (-0.64%)

14:08
07/16/18
07/16
14:08
07/16/18
14:08
Recommendations
J.B. Hunt analyst commentary  »

Loop says J.B. Hunt…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

SYRS

Syros Pharmaceuticals

$12.35

(0.00%)

14:08
07/16/18
07/16
14:08
07/16/18
14:08
Conference/Events
Syros Pharmaceuticals to hold a key opinion leader meeting »

Key Opinion Leader…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

EQGP

EQT GP

$24.87

-0.25 (-1.00%)

, EQM

EQT Midstream Partners

$54.90

0.49 (0.90%)

14:02
07/16/18
07/16
14:02
07/16/18
14:02
Conference/Events
Rice Midstream to host special shareholder meeting »

Special Shareholder…

EQGP

EQT GP

$24.87

-0.25 (-1.00%)

EQM

EQT Midstream Partners

$54.90

0.49 (0.90%)

RMP

Rice Midstream

$18.16

0.16 (0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 26

    Jul

CRSP

Crispr Therapeutics

$59.61

-6.13 (-9.32%)

14:01
07/16/18
07/16
14:01
07/16/18
14:01
Periodicals
Crispr Therapeutics tells CNBC does not use methods described in paper »

Crispr Therapeutics told…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAS

Masco

$37.79

-0.22 (-0.58%)

14:00
07/16/18
07/16
14:00
07/16/18
14:00
Options
Bullish option play opened in Masco ahead of earnings »

Bullish option play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

CRSP

Crispr Therapeutics

$59.09

-6.65 (-10.12%)

13:55
07/16/18
07/16
13:55
07/16/18
13:55
Options
Crispr Therapeutics put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:50
07/16/18
07/16
13:50
07/16/18
13:50
General news
U.S. equities are up from earlier lows »

U.S. equities are up from…

ECA

Encana

$12.84

-0.4 (-3.02%)

13:45
07/16/18
07/16
13:45
07/16/18
13:45
Options
Encana call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

  • 09

    Oct

ADS

Alliance Data

$220.17

-23.32 (-9.58%)

13:44
07/16/18
07/16
13:44
07/16/18
13:44
Technical Analysis
Technical Take: Alliance Data comes off the lows of the day »

Shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 08

    Aug

CRM

Salesforce

$147.50

-0.18 (-0.12%)

13:39
07/16/18
07/16
13:39
07/16/18
13:39
Hot Stocks
Salesforce announces definitive agreement to acquire Datorama »

Salesforce has signed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 16

    Aug

YELP

Yelp

$40.33

0.54 (1.36%)

13:35
07/16/18
07/16
13:35
07/16/18
13:35
Options
Yelp put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LBIX

Leading Brands

$1.62

-0.06 (-3.57%)

13:32
07/16/18
07/16
13:32
07/16/18
13:32
Hot Stocks
Leading Brands announces resolution of temporary non-compliance with Nasdaq rule »

Leading Brands announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STM

STMicroelectronics

$22.84

0.2 (0.88%)

13:25
07/16/18
07/16
13:25
07/16/18
13:25
Options
STMicroelectronics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

13:25
07/16/18
07/16
13:25
07/16/18
13:25
Conference/Events
Stephens agricultural analyst to hold an analyst/industry conference call »

Agriculture, Chemicals,…

EDIT

Editas Medicine

$36.20

-1.71 (-4.51%)

, NTLA

Intellia Therapeutics

$30.55

-2.05 (-6.29%)

13:23
07/16/18
07/16
13:23
07/16/18
13:23
Periodicals
Editas tells CNBC 'not specifically concerned about' Crisper study »

Editas Medicine (EDIT)…

EDIT

Editas Medicine

$36.20

-1.71 (-4.51%)

NTLA

Intellia Therapeutics

$30.55

-2.05 (-6.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVS

CVS Health

$68.30

-0.33 (-0.48%)

13:19
07/16/18
07/16
13:19
07/16/18
13:19
Periodicals
CVS apologizes after store managers call police on black customer, AP says »

CVS Health is apologizing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
07/16/18
07/16
13:17
07/16/18
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
07/16/18
07/16
13:16
07/16/18
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.